Abstract:Icariin and icariside II (ICA II), 2 active components isolated from herba epimedii, have a closely structural relationship. There is evidence that icariin may be useful in the treatment of erectile dysfunction (ED); however, the study on the therapeutic efficacy of ICA II on ED is currently scant. We investigated the effects of ICA II on improving erectile function of rats with streptozocin-induced diabetes. Fifty 8-week-old Sprague-Dawley rats were randomly distributed into normal control and diabetic groups. Diabetes was induced by a one-time intraperitoneal injection of streptozocin (60 mg/kg). Three days later, the diabetic rats were randomly divided into 4 groups including a saline-treated placebo arm and 3 ICA II treated models (1, 5, and 10 mg/kg/d). After 3 months, penile hemodynamics was measured by cavernous nerve electrostimulation (CNE) with real time intracorporal pressure assessment. Penises were harvested with subsequent histological examination (picrosirius red stain, Hart elastin stain, and immunohistochemical stain) and Western blots to explore the expression of the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) and transforming growth factor beta 1 (TGF beta 1)/Smad2 signaling pathways. Diabetes significantly attenuated erectile responses to CNE. Diabetic rats had decreased corpus cavernosum smooth muscle/collagen ratio and endothelial cell content relative to the control group. The ratio of collagen I to III was significantly lower in the corpora of diabetic rats; furthermore, cavernous elastic fibers were fragmented in the diabetic animals. Neuronal nitric oxide synthase (nNOS), endothelial nitric oxide synthase, and vascular endothelial growth factor were expressed at lower levels in the diabetic group; ICA II-treated diabetic rats had higher expression in the penis relative to placebo-treated diabetic animals. Both the TGF beta 1/Smad2/connective tissue growth factor (CTGF) signaling pathway and apoptosis were down-regulated in the penis from ICA II-treated rats. ICA II treatment attenuates diabetes-related impairment of penile hemodynamics, likely by increasing smooth muscle, endothelial function, and nNOS expression. ICA II could alter corpus cavernosum fibrous-muscular pathological structure in diabetic rats, which could be regulated by the TGF beta 1/Smad2/CTGF and NO-cGMP signaling pathways.

AB209. Prophylactic Protective Effects and Its Potential Mechanisms of Icariside II on Streptozotocin Induced Spermatogenic Dysfunction.

AB176. Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats

Effects Of Icariside Ii On Corpus Cavernosum And Major Pelvic Ganglion Neuropathy In Streptozotocin-Induced Diabetic Rats

AB178. Molecular Biology for Genitourinary System Diseases and Sexual Dysfunction Icariside II Prevents High-Glucose-induced Injury on Human Cavernous Endothelial Cells Through Akt-eNOS Signaling Pathway

Effects of Icariside II on Improving Erectile Function in Rats with Streptozotocin-Induced Diabetes.

Icariin protects testicular damage in streptozotocin-induced diabetic rats through regulation of glycolysis pathway

Preparation of Two Derivatives from Icariin and Investigation of Their Estrogen-Like Effects

Effect of Icarisid II on Diabetic Rats with Erectile Dysfunction and Its Potential Mechanism Via Assessment of AGEs, Autophagy, Mtor and the NO-cGMP Pathway.

AB208. Antioxidant Icariside II Combined with Insulin Restores Erectile Function in Streptozotocin-Induced Type 1 Diabetic Rats

Effect of Icariside II and Metformin on Penile Erectile Function, Glucose Metabolism, Reaction Oxygen Species, Superoxide Dismutase, and Mitochondrial Autophagy in Type 2 Diabetic Rats with Erectile Dysfunction

The protective effects of icariin against testicular dysfunction in type 1 diabetic mice Via AMPK-mediated Nrf2 activation and NF-κB p65 inhibition

Integrative proteomics and metabolomics approach to identify the key roles of icariin-mediated protective effects against cyclophosphamide-induced spermatogenesis dysfunction in mice

AB238. Effect of Icariside II on miR-126 pathway on human cavernous endothelial cells exposed to a diabetic-like environment

Icariin Ameliorates Streptozotocin-Induced Diabetic Retinopathy in Vitro and in Vivo

Icariside Ii Prevents High-Glucose-Induced Injury On Human Cavernous Endothelial Cells Through Akt-Enos Signaling Pathway

Icariside II: Anticancer Potential and Molecular Targets in Solid Cancers

Anticancer Effect of Icaritin on Human Lung Cancer Cells Through Inducing S Phase Cell Cycle Arrest and Apoptosis.

Effects of paeoniflorin on neurobehavior, oxidative stress, brain insulin signaling, and synaptic alterations in intracerebroventricular streptozotocin-induced cognitive impairment in mice

The Effect of Cilostazol on Expression of Thrombospondin-1 in Diabetic Retinopathy.

AB037. Icariside II improves human cavernous endothelial cells function by regulating miR-155/eNOS signal pathway

AB239. Icariside II enhances endothelial nitric oxide synthase expression by suppressing miR-155 in diabetic-like human cavernous endothelial cells